Literature DB >> 15050488

Relation between contractile reserve and improvement in left ventricular function with beta-blocker therapy in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.

Frank F Seghatol1, Dipan J Shah, Silvia Diluzio, David Bello, Maryl R Johnson, William G Cotts, Jenny A O'Donohue, Robert O Bonow, Mihai Gheorghiade, Vera H Rigolin.   

Abstract

Beta blockers improve left ventricular (LV) ejection fraction but patient responses are heterogenous. We investigated the role of contractile reserve (CR) in predicting beta-blocker response in ischemic and nonischemic cardiomyopathy. Resting and low-dose dobutamine echocardiograms were recorded in 32 patients with heart failure (LV ejection fraction <or=35%), 18 with ischemic cardiomyopathy (IC), and 14 with idiopathic dilated cardiomyopathy (IDC). A segment was defined as CR positive (CR+) or negative (CR-) based on response to dobutamine. Patients were then classified as CR+ or CR- based on number of improved segments (IC group) or ejection fraction improvement (IDC group) in response to dobutamine. During follow-up (2, 6, and 14 months after beta-blocker initiation), response was measured by the percent of segments showing improved contractility from baseline, ejection fraction, and wall motion score index. In the IC group, the percent of improved segments was greater at 2 and 6 months in CR+ versus CR- (70% vs 15% and 39% vs 17%, p <0.05), whereas it was greater at all periods in the patients with IDC (36% vs 9% at 2 months, 50% vs 19% at 6 months, and 63% vs 42% at 14 months, p <0.05). Findings for ejection fraction and wall motion score index were similar. Therefore, time course and magnitude of improvement in LV function in patients with heart failure receiving beta blockers are related to CR status. CR predicts a greater early response in IC, whereas it predicts a greater response at all time periods in IDC. However, even patients without CR showed improvement in LV function at 14 months.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15050488     DOI: 10.1016/j.amjcard.2003.12.023

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

Review 1.  Dobutamine stress echocardiography: does it predict response to beta-blockers in patients with heart failure?

Authors:  Sripal Bangalore; Khashayar Hematpour; Farooq A Chaudhry
Journal:  Curr Heart Fail Rep       Date:  2006-06

2.  Myocardial viability testing: still viable after stich?

Authors:  Robert O Bonow; Thomas A Holly
Journal:  J Nucl Cardiol       Date:  2011-12       Impact factor: 5.952

3.  Myocardial viability and survival in ischemic left ventricular dysfunction.

Authors:  Robert O Bonow; Gerald Maurer; Kerry L Lee; Thomas A Holly; Philip F Binkley; Patrice Desvigne-Nickens; Jaroslaw Drozdz; Pedro S Farsky; Arthur M Feldman; Torsten Doenst; Robert E Michler; Daniel S Berman; Jose C Nicolau; Patricia A Pellikka; Krzysztof Wrobel; Nasri Alotti; Federico M Asch; Liliana E Favaloro; Lilin She; Eric J Velazquez; Robert H Jones; Julio A Panza
Journal:  N Engl J Med       Date:  2011-04-04       Impact factor: 91.245

4.  Head-to-head comparison of indices of left ventricular contractile reserve assessed by high-dose dobutamine stress echocardiography in idiopathic dilated cardiomyopathy: five-year follow up.

Authors:  P Otasevic; Z B Popovic; J D Vasiljevic; L Pratali; A Vlahovic-Stipac; S D Boskovic; N Tasic; A N Neskovic
Journal:  Heart       Date:  2006-01-31       Impact factor: 5.994

5.  Presence of left ventricular contractile reserve, evaluated by means of dobutamine stress-echo test, is able to predict response to cardiac resynchronization therapy.

Authors:  Bernardino Tuccillo; Carmine Muto; Raffaele Iengo; Maria Accadia; Salvatore Rumolo; Micheleangelo Canciello; Giovanni Carreras; Raimondo Calvanese; Eduardo Celentano; Mario Davinelli; Sergio Valsecchi; Luigi Ascione
Journal:  J Interv Card Electrophysiol       Date:  2008-06-28       Impact factor: 1.900

6.  MR assessment of myocardial perfusion, viability, and function after intramyocardial transfer of VM202, a new plasmid human hepatocyte growth factor in ischemic swine myocardium.

Authors:  Maythem Saeed; Alastair Martin; Phillip Ursell; Loi Do; Matt Bucknor; Charles B Higgins; David Saloner
Journal:  Radiology       Date:  2008-08-05       Impact factor: 11.105

7.  Systolic dysfunction portends increased mortality among those waiting for renal transplant.

Authors:  Angelo M de Mattos; Andrew Siedlecki; Robert S Gaston; Gilbert J Perry; Bruce A Julian; Clifton E Kew; Mark H Deierhoi; Carlton Young; John J Curtis; Ami E Iskandrian
Journal:  J Am Soc Nephrol       Date:  2008-03-27       Impact factor: 10.121

8.  Severity of Remodeling, Myocardial Viability, and Survival in Ischemic LV Dysfunction After Surgical Revascularization.

Authors:  Robert O Bonow; Serenella Castelvecchio; Julio A Panza; Daniel S Berman; Eric J Velazquez; Robert E Michler; Lilin She; Thomas A Holly; Patrice Desvigne-Nickens; Dragana Kosevic; Miroslaw Rajda; Lukasz Chrzanowski; Marek Deja; Kerry L Lee; Harvey White; Jae K Oh; Torsten Doenst; James A Hill; Jean L Rouleau; Lorenzo Menicanti
Journal:  JACC Cardiovasc Imaging       Date:  2015-09-09

9.  β1 adrenergic receptor polymorphisms and heart failure: a meta-analysis on susceptibility, response to β-blocker therapy and prognosis.

Authors:  Wen-Nan Liu; Kai-Li Fu; Hai-Yang Gao; Yuan-Yuan Shang; Zhi-Hao Wang; Gui-Hua Jiang; Yun Zhang; Wei Zhang; Ming Zhong
Journal:  PLoS One       Date:  2012-07-17       Impact factor: 3.240

10.  Relation between regional and global systolic function in patients with ischemic cardiomyopathy after beta-blocker therapy or revascularization.

Authors:  T A M Kaandorp; J J Bax; S E Bleeker; J Doornbos; E P Viergever; D Poldermans; E E van der Wall; A de Roos; H J Lamb
Journal:  J Cardiovasc Magn Reson       Date:  2010-01-27       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.